Efficacy and Safety of Paclitaxel, Ifosfamide and Cisplatin as First-line Treatment on Patients with Intermediate- or Poor-risk Advanced Testicular Cancer

• Main Authors: ZHOU Li, CHI Zhihong, CUI Chuanliang, SHENG Xi'nan, SI Lu, TANG Bixia, MAO Lili, WANG Xuan, YAN Xieqiao, LIAN Bin, LI Siming, BAI Xue, GUO Jun
• Format: Article
• Language: zho
• Published: Magazine House of Cancer Research on Prevention and Treatment 2018-06-01
• Series: Zhongliu Fangzhi Yanjiu
• Subjects: testicular cancer; germ cell tumors; first-line treatment; paclitaxel
• Online Access: http://html.rhhz.net/ZLFZYJ/html/8578.2018.17.1417.htm

Objective To assess the efficacy and safety of paclitaxel, ifosfamide and cisplatin (TIP) as the first-line treatment for the patients with intermediate- or poor-risk testicular cancer retrospectively. Methods Patients with intermediate- or poor-risk testicular cancer in our center received TIP as the first-line treatment. Objective response rate, 2-year progression free survival(PFS) and overall survival(OS) were evaluated. Results The mean treatment of 20 patients was 4.25cycles. Six patients achieved CR(30%), seven patients had partial response(35%) and overall response rate was 65%. The median follow-up time was 25 months. Three patients died of tumor progression. Hematologic toxicity was most common(95%), with 30% of grade 3-4 neutropenia. Estimated 2-year PFS was 72.9% and OS was 89.1%. Conclusion Paclitaxel, ifosfamide and cisplatin(TIP) are safe and effective as the first-line treatment on patients with intermediate- or poor-risk testicular cancer. Compared with previous studies, 2-year PFS and OS have been improved. Adverse effect could be controlled. Further researches are still needed.